Right meh...aiyo better investment in Duopharm Biotech DBB la...
PETALING JAYA: The healthcare sector could still hold potential for those who have yet to buy into the sector.
Healthcare stocks such as IHH Healthcare Bhd and Duopharma Biotech Bhd (DBB) may still have have further room to run, premised upon new growth drivers and structurally higher cost of care, according to analysts.
RHB Investment Bank Bhd Research said it believes valuations remain undemanding for IHH despite its stellar performance, while DBB is expected to rerate once vaccine noise subsides.
Its top pick is IHH, premised on its defensive demand, with diversified presence and anticipated operational recovery from its lagging markets (Malaysia and Singapore).
“Looking beyond the recovery, we believe there could be additional upside (not captured in our target price) from IHH management’s restructuring efforts, that will boost its return on equity (ROE)-enhancing strategy,” said RHB Research in a report.
As price reaches 350, it constantly attack by foreign media. That key level 350 is the breaking point plus CPO hitting all time high will catalyst this share price to rm550 & above. What is their hidden agenda?
Please, read that the current div of 20 ct is 2nd .interim div for 3rd.quarter ! Most likely, there will be a final div to be declared in Feb 2022 for 4th.q result which will sure exceed $103m profit made in 3rd.q. due to rising price of CPO and Timber in the world !!!
Today most big cap plantations are in the red bcoz palm oil futures fell sharply but Taan is holding up strongly mainly bcoz of the 20 sen dividend. I have a strong feeling that there could be a correction soon after the div gone ex !
Either,Titan unaware or,to mislead, but analysts more upbeat on its price upward ! Palm oil bulls to roar into 2022 on labour crunch, La Nina deluge 13 hours ago 35
All foreign media and activist troll ‐--------- all disappeared. Big buyer emerged to collect...for investment! Sometimes is good for Gov to act..and defend CPO industry.
Plantbull and Abba most palm oil futures were lower when I viewed the bursa derivatives market yesterday morning no BS . I am also a substantial holder of Taan but looking at the trading pattern of this stock I will confidently say it will go below RM3.30 when it goes ex you can choose not to believe but that is my opinion
Having said that Taan is still a good stock to invest for its generous dividend at least for the next 12 months but there are people who is not that happy with a yield of 8 to 9 % and of course there are manipulators too
@ Pinky it may drop to below 3.10 before the announement of the next qtr result and dividend payment but not too sure about tomorrow's performance coz today palm oil futures closed pretty strong
@Pinky I keyed in to sell 3.38 this morning but was done at 3.40 thereafter it is all the way down. Have said earlier today performane would not be that bad but along the way it will slide
The downsides to most Msian companies are the ESG and cukai makmur and plantations are not exempted. Most funds are pissed off with the additional 33% cukai makmuk on top of the corporate tax starting next year although it is claimed for one off kind of things only but for retailers they keep looking for decent returns for their money taan seems to fit the bill therefore you will also see some tussles along the way. Just look at IOI and sime darby plantation you will understsnd
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
stockraider
31,556 posts
Posted by stockraider > 2021-12-24 13:39 | Report Abuse
I have my reservation for this type of bumi stock loh!
Posted by uncensored > Dec 24, 2021 1:34 PM | Report Abuse
https://www.thestar.com.my/business/business-news/2021/12/23/a-healthy...
Right meh...aiyo better investment in Duopharm Biotech DBB la...
PETALING JAYA: The healthcare sector could still hold potential for those who have yet to buy into the sector.
Healthcare stocks such as IHH Healthcare Bhd and Duopharma Biotech Bhd (DBB) may still have have further room to run, premised upon new growth drivers and structurally higher cost of care, according to analysts.
RHB Investment Bank Bhd Research said it believes valuations remain undemanding for IHH despite its stellar performance, while DBB is expected to rerate once vaccine noise subsides.
Its top pick is IHH, premised on its defensive demand, with diversified presence and anticipated operational recovery from its lagging markets (Malaysia and Singapore).
“Looking beyond the recovery, we believe there could be additional upside (not captured in our target price) from IHH management’s restructuring efforts, that will boost its return on equity (ROE)-enhancing strategy,” said RHB Research in a report.